Double-blind placebo-controlled trial of adjuvant pamidronate with palliative radiotherapy and intravenous doxorubicin for canine appendicular osteosarcoma bone pain

Journal of Veterinary Internal Medicine

Volumn 23, Issue 1, 2009, Pages 152-160

  Fan, T M ^a   Charney, S C ^a   De Lorimier, L P ^a,b   Garrett, L D ^a   Griffon, D J ^a   Gordon Evans, W J ^a   Wypij, J M ^a  

^a UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

^b Hôpital Vétérinaire Rive Sud   (Canada)

Author keywords

Aminobisphosphonate; Bone sarcoma; Dual energy X ray absorptiometry; Malignant osteolysis; Pain alleviation; Urine N telopeptide

Indexed keywords

ANALGESIC AGENT; ANTINEOPLASTIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; BONE DENSITY CONSERVATION AGENT; DOXORUBICIN; PAMIDRONIC ACID;

ANALGESIA; ANIMAL; ANIMAL DISEASE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOG; DOG DISEASE; DOUBLE BLIND PROCEDURE; FEMALE; LIMB; MALE; OSTEOSARCOMA; PAIN; PATHOLOGY; RADIOTHERAPY; RANDOMIZED CONTROLLED TRIAL;

ANALGESIA; ANALGESICS; ANIMALS; ANTINEOPLASTIC AGENTS; BONE DENSITY CONSERVATION AGENTS; DIPHOSPHONATES; DOG DISEASES; DOGS; DOUBLE-BLIND METHOD; DOXORUBICIN; EXTREMITIES; FEMALE; MALE; OSTEOSARCOMA; PAIN; RADIOTHERAPY;

ANIMALIA; CANIS FAMILIARIS;

EID: 61349136972     PISSN: 08916640     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1939-1676.2008.0221.x     Document Type: Article

References (35)

1. Clohisy DR, Mantyh PW. Bone cancer pain. Cancer 2003;97: 866-873.
2. Mantyh PW, Clohisy DR, Koltzenburg M, et al. Molecular mechanisms of cancer pain. Nat Rev Cancer 2002;2:201-209.
3. Clohisy DR, Mantyh PW. Bone cancer pain and the role of RANKL/OPG. J Musculoskelet Neuronal Interact 2004;4:293-300.
4. Goblirsch M, Mathews W, Lynch C, et al. Radiation treatment decreases bone cancer pain, osteolysis and tumor size. Radiat Res 2004;161:228-234.
5. Luger NM, Honore P, Sabino MA, et al. Osteoprotegerin diminishes advanced bone cancer pain. Cancer Res 2001;61:4038-4047.
6. Goblirsch M, Lynch C, Mathews W, et al. Radiation treatment decreases bone cancer pain through direct effect on tumor cells. Radiat Res 2005;164:400-408.
7. Farese JP, Milner R, Thompson MS, et al. Stereotactic radiosurgery for treatment of osteosarcomas involving the distal portions of the limbs in dogs. J Am Vet Med Assoc 2004;225:1567-1572.
8. Green EM, Adams WM, Forrest LJ. Four fraction palliative radiotherapy for osteosarcoma in 24 dogs. J Am Anim Hosp Assoc 2002;38:445-451.
9. Mayer MN, Grier CK. Palliative radiation therapy for canine osteosarcoma. Can Vet J 2006;47:707-709.
10. Milner RJ, Dormehl I, Louw WK, et al. Targeted radiotherapy with Sm-153-EDTMP in nine cases of canine primary bone tumours. J South Afr Vet Assoc 1998;69:12-17.
11. Mueller F, Poirier V, Melzer K, et al. Palliative radiotherapy with electrons of appendicular osteosarcoma in 54 dogs. In Vivo 2005;19:713-716.
12. Ramirez O 111, Dodge RK, Page RL, et al. Palliative radiotherapy of appendicular osteosarcoma in 95 dogs. Vet Radiol Ultrasound 1999;40:517-522.
13. Powers BE, Withrow SJ, Thrall DE, et al. Percent tumor necrosis as a predictor oftreatment response in canine osteosarcoma. Cancer 1991;67:126-134.
14. ithrow SJ, Thrall DE, Straw RC, et al. Intra-arterial cisplatin with or without radiation in limb-sparing for canine osteosarcoma. Cancer 1993;71:2484-2490.
15. Luckman SP, Hughes DE, Coxon FP, et al. Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras. J Bone Miner Res 1998;13:581-589.
16. Rogers MJ, Gordon S, Benford HL, et al. Cellular and molecular mechanisms of action of bisphosphonates. Cancer 2000;88:2961-2978.
17. Saad F, Lipton A. Clinical benefits and considerations of bisphosphonate treatment in metastatic bone disease. Semin Oncol 2007;34:S17-S23.
18. Fan TM, de Lorimier LP, Charney SC, et al. Evaluation of intravenous pamidronate administration in 33 cancer-bearing dogs with primary or secondary bone involvement. J Vet Intern Med 2005;19:74-80.
19. Fan TM, de Lorimier LP, Garrett LD, et al. The bone biologic effects of zoledronate in healthy dogs and dogs with malignant osteolysis. J Vet Intern Med 2008;22:380-387.
20. Fan TM, de Lorimier LP, O'Dell-Anderson K, et al. Single-agent pamidronate for palliative therapy of canine appendicular osteosarcoma bone pain. J Vet Intern Med 2007;21:431-439.
21. Hudson JT, Slater MR, Taylor L, et al. Assessing repeatability and validity of a visual analogue scale questionnaire for use in assessing pain and lameness in dogs. Am J Vet Res 2004;65:1634-1643.
22. Brown JE, Cook RJ, Major P, et al. Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors. J Natl Cancer Inst 2005;97:59-69.
23. Coleman RE, Major P, Lipton A, et al. Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid. J Clin Oncol 2005;23:4925-4935.
24. Berruti A, Dogliotti L, Osella G, et al. Evaluation by dual energy X-ray absorptiometry of changed bone density in metastatic bone sites as a consequence of systemic treatment. Oncol Rep 2000;7:777-781.
25. Shapiro CL, Keating J, Angell JE, et al. Monitoring therapeutic response in skeletal metastases using dual-energy X-ray absorptiometry: A prospective feasibility study in breast cancer patients. Cancer Invest 1999;17:566-574.
26. Smith GL, Doherty AP, Banks LM, et al. Dual X-ray absorptiometry detects disease- and treatment-related alterations of bone density in prostate cancer patients. Clin Exp Metastasis 2000;18:385-390.
27. Horstman CL, Conzemius MG, Evans R, et al. Assessing the efficacy of perioperative oral carprofen after cranial cruciate surgery using noninvasive, objective pressure platform gait analysis. Vet Surg 2004;33:286-292.
28. Barger A, Graca R, Bailey K, et al. Use of alkaline phosphatase staining to differentiate canine osteosarcoma from other vimentin-positive tumors. Vet Pathol 2005;42:161-165.
29. Allen MJ, Allen LC, Hoffmann WE, et al. Urinary markers of type I collagen degradation in the dog. Res Vet Sci 2000;69:123-127.
30. Ladlow JF, Hoffmann WE, Breur GJ, et al. Biological variability in serum and urinary indices of bone formation and resorptionin dogs. Calcif Tissue Int 2002;70:186-193.
31. Arrington SA, Damron TA, Mann KA, et al. Concurrent administration of zoledronic acid and irradiation leads to improved bone density, biomechanical strength, and microarchitecture in a mouse model of tumor-induced osteolysis. J Surg Oncol 2008;97:284-290.
32. Krempien R, Huber PE, Harms W, et al. Combination of early bisphosphonate administration and irradiation leads to improved remineralization and restabilization of osteolytic bone metastases in an animal tumor model. Cancer 2003;98:1318-1324.
33. George R, Hephzibah J, John S. Does pamidronate enhance the analgesic effect of radiotherapy? A randomized trial. Palliat Med 2007;21:719-720.
34. Hartsell WF, Scott CB, Bruner DW, et al. Randomized trial of short- versus long-course radiotherapy for palliation of painful bone metastases. J Natl Cancer Inst 2005;97:798-804.
35. Kouloulias EV, Kouvaris RJ, Antypas C, et al. An intra-patient dose-escalation study of disodium pamidronate plus radiotherapy versus radiotherapy alone for the treatment of osteolytic metastases. Monitoring of recalcification using image-processing techniques. Strahlenther Onkol 2003;179:471-479.